Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06098794 |
| Other study ID # |
RepSprintsSodiumBicarbonate |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
October 15, 2021 |
| Est. completion date |
April 27, 2022 |
Study information
| Verified date |
October 2023 |
| Source |
Faculdade de Motricidade Humana |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This was a randomized, double-blind, placebo controlled, crossover trial. The study aimed to
assess the effect of sodium bicarbonate on the ability to perform a repeated sprint task by
female football players. The researches hypothesis was that sodium bicarbonate increases the
ability to remove lactic acid from muscle cells reducing its intracellular accumulation and
increasing energetic efficiency resulting in the increase of peak power output, mean power
output, or total work or in the decrease of the sprint decrement in each set of the repeated
sprints task.
Description:
Experimental design: The study consisted of a randomized, double-blind, controlled, crossover
trial where 11 female football players performed, in a randomized order, two repeated sprints
tasks in a cycle ergometer, after having ingested either sodium bicarbonate (SB) or placebo
(PL). Body composition of the athletes was characterized by bioelectrical impedance analysis
with a single frequency (50 kHz) device (BIA 101 Anniversary, Akern, Florence, Italy) before
the exercise sessions. Data collection was separated by a period of at least one week within
a period of time not exceeding one month and performed at the same time of the day for each
participant. Data regarding performance, blood lactate accumulation, pulmonary gas exchange,
heart rate (HR), muscle oxygenation and neuromuscular fatigue were collected during these two
sessions.
Supplementation protocol: The participants ingested capsules containing 0.3 g/kg of body
weight of SB or cellulose as PL divided into two doses. The first intake (0.2 g/kg) occurred
2 h before the beginning of the protocol, and the second (0.1 g/kg) occurred 1 h later.
Possible gastrointestinal symptoms associated with supplement ingestion were controlled with
a questionnaire based on the questionnaire applied by Miller et al. (2016).
Repeated sprints protocol: The RSA protocol was performed in a cycle ergometer (Monark
Ergomedic 894 E, Monark Exercise AB, Vansbro, Sweden) and was composed of 3 sets of 6 sprints
with 6 s duration with a workload of 4% of the body mass. Repetitions were separated by 24 s
of active recovery, and participants were conceded 5 min of passive recovery to rest between
sets. The protocol was preceded by a 5-min warm-up in which athletes pedalled at a speed of
60 to 70 rpm.
Performance Measurements: Performance was evaluated by monitoring peak power output, mean
power output, total work and the sprint decrement in each set of the two repeated sprints
task.
Blood lactate accumulation: Lactate concentration was assessed (Lactate Pro 2, KDK
Corporation, Kyoto, Japan) in capillary blood from the ear lobe before the beginning of each
protocol, 1 min after the end of each set, and at min 1 and every 2 min after the tasks were
completed, until the value started to decrease. At the end of the tasks, the maximal values
achieved were considered for analysis.
Pulmonary gas exchange and heart rate: Oxygen uptake, carbon dioxide production and
ventilation (VO2, VCO2, VE, respectively) were measured breath-by-breath, during the
protocol, using a gas analyser (MetaMax 3B, Cortex Biophysik, Leipzig, Germany). Heart rate
was continuously evaluated using an HR monitor (H7, Polar Electro Oy, Kempele, Finland). The
integral of VO2 (L) and VCO2 (L) and the maximum 6-s moving average of relative VO2
(mL/kg.min), VE (L/min) and HR (bpm) were calculated for each set.
Muscle oxygenation: Throughout the protocol, oxygenated (O2Hb) and deoxygenated haemoglobin
(HHb) were continuously monitored with a near-infrared spectroscopy device (Niro-200NX,
Hamamatsu Phototonics, Hamamatsu, Japan) according with the manufacturer specifications. The
integrals of O2Hb and HHb were calculated for each set of the protocol.
Neuromuscular fatigue assessment: Athletes executed a countermovement jump (CMJ) in a contact
mat (Chronojump BoscoSystem, Software Version 2.2.0, Barcelona, Spain) before and after the
exercise protocol, accessing values of jump height (JH). Three jumps were performed,
separated by 30 s of rest, and the best jump was considered for analysis.
Data analysis: Power and sample calculations (G-Power, Version 3.1.9.2, Düsseldorf, Germany)
were based on an effect size of 0.88 (McNaughton et al., 1997) for total work performed in
the sprints, a power of 0.85 and a significance of 0.05. After the recruitment process, 12
athletes volunteered to participate in the study. One volunteer withdrew due to injury,
leading to a sample size of 11 athletes. Statistical analysis was performed using the
Statistical Package for the Social Sciences (IBM Corp, SPSS v27.0, Armonk, NY, USA) and R
software (v4.2.0, Open-Source Code, General Public License). Normal distribution and
sphericity were tested using Shapiro-Wilk's and Mauchly's tests, respectively. For variables
with normal distribution, data was analysed using a two-way analysis of variance (ANOVA).
Whenever a statistical significance was observed in the two-way ANOVA, post-hoc paired
comparisons were performed with the Bonferroni correction. Statistical significance was set
at p < 0.05. If normal distribution was not verified, the nparLD module of the R software was
used to perform a non-parametric two-way ANOVA-type test and if any significant result was
observed, a Friedman test and the post-hoc paired comparisons with the Bonferroni correction
as well as a Wilcoxon test were performed. Statistical significance was adjusted according
with the number of tests performed for each factor.
